Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETECT: Biomarker of Vedolizumab Efficacy in Ulcerative Colitis
NCT02878083Terminated
- Sponsor
- CHU de Nantes
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of vedolizumab in ulcerative colitis (UC), sponsored by CHU de Nantes. Primary endpoint: Feasibility of an ex vivo labeling of intestinal immune cells with a combination of two markers: vedolizumab-FITC and adalimumab-Alexa Fluor 647 at Week 0. Started Jan 2017; status: terminated.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02878083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02878083.